Sandaruwan Geeganage

1.9k total citations
21 papers, 1.0k citations indexed

About

Sandaruwan Geeganage is a scholar working on Molecular Biology, Oncology and Clinical Biochemistry. According to data from OpenAlex, Sandaruwan Geeganage has authored 21 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Molecular Biology, 6 papers in Oncology and 5 papers in Clinical Biochemistry. Recurrent topics in Sandaruwan Geeganage's work include Metabolism and Genetic Disorders (5 papers), PI3K/AKT/mTOR signaling in cancer (5 papers) and Amino Acid Enzymes and Metabolism (4 papers). Sandaruwan Geeganage is often cited by papers focused on Metabolism and Genetic Disorders (5 papers), PI3K/AKT/mTOR signaling in cancer (5 papers) and Amino Acid Enzymes and Metabolism (4 papers). Sandaruwan Geeganage collaborates with scholars based in United States, Canada and Spain. Sandaruwan Geeganage's co-authors include Michael Flagella, Lawrence M. Gelbert, Jennifer D. Davidson, Christopher A. Slapak, Liandong Ma, Karen Huss, Perry A. Frey, Lillian Sams, Andrew Capen and Bruce W. Konicek and has published in prestigious journals such as Journal of Biological Chemistry, Biochemistry and Cancer Research.

In The Last Decade

Sandaruwan Geeganage

21 papers receiving 997 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Sandaruwan Geeganage United States 11 626 361 195 179 120 21 1.0k
Timothy G. Whitsett United States 18 527 0.8× 247 0.7× 266 1.4× 239 1.3× 102 0.8× 35 996
Estefanía Carrasco‐García Spain 25 817 1.3× 387 1.1× 412 2.1× 116 0.6× 223 1.9× 37 1.4k
Yidan Ren China 14 622 1.0× 252 0.7× 307 1.6× 121 0.7× 43 0.4× 23 1.0k
Qinlian Jiao China 11 508 0.8× 240 0.7× 245 1.3× 104 0.6× 43 0.4× 17 838
Bojie Dai United States 18 697 1.1× 194 0.5× 193 1.0× 264 1.5× 51 0.4× 30 1.1k
David Cerna United States 18 750 1.2× 297 0.8× 250 1.3× 157 0.9× 166 1.4× 22 1.1k
Ji Nie China 10 748 1.2× 327 0.9× 242 1.2× 232 1.3× 118 1.0× 12 1.3k
Wei Wei Prior United States 8 644 1.0× 199 0.6× 91 0.5× 147 0.8× 131 1.1× 10 888
Demetra Constantinidou United Kingdom 5 1.1k 1.7× 495 1.4× 188 1.0× 176 1.0× 39 0.3× 6 1.4k

Countries citing papers authored by Sandaruwan Geeganage

Since Specialization
Citations

This map shows the geographic impact of Sandaruwan Geeganage's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sandaruwan Geeganage with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sandaruwan Geeganage more than expected).

Fields of papers citing papers by Sandaruwan Geeganage

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sandaruwan Geeganage. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sandaruwan Geeganage. The network helps show where Sandaruwan Geeganage may publish in the future.

Co-authorship network of co-authors of Sandaruwan Geeganage

This figure shows the co-authorship network connecting the top 25 collaborators of Sandaruwan Geeganage. A scholar is included among the top collaborators of Sandaruwan Geeganage based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sandaruwan Geeganage. Sandaruwan Geeganage is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Kotecki, Nuria, Perrine Vuagnat, Bert H. O’Neil, et al.. (2021). A Phase I Study of an IDO-1 Inhibitor (LY3381916) as Monotherapy and in Combination With an Anti-PD-L1 Antibody (LY3300054) in Patients With Advanced Cancer. Journal of Immunotherapy. 44(7). 264–275. 29 indexed citations
2.
3.
Geeganage, Sandaruwan, Lillian Sams, James L. Henry, et al.. (2019). Abstract 2187: Tryptophan Metabolism Plays a Central Role in Immunosuppression. 2187–2187. 1 indexed citations
4.
Geeganage, Sandaruwan, Lillian Sams, James R. Henry, et al.. (2019). Abstract 2187: Tryptophan Metabolism Plays a Central Role in Immunosuppression. Cancer Research. 79(13_Supplement). 2187–2187. 2 indexed citations
5.
Henry, Kenneth J., Óscar de Frutos, Pablo D. García, et al.. (2018). Discovery of chiral dihydropyridopyrimidinones as potent, selective and orally bioavailable inhibitors of AKT. Bioorganic & Medicinal Chemistry Letters. 28(10). 1887–1891. 9 indexed citations
6.
Dorsey, Frank C., Karim A. Benhadji, Lillian Sams, et al.. (2018). Abstract 5245: Identification and characterization of the IDO1 inhibitor LY3381916. Cancer Research. 78(13_Supplement). 5245–5245. 13 indexed citations
7.
Novosiadly, Ruslan D., David Schaer, Nelusha Amaladas, et al.. (2018). Abstract 4549: Pemetrexed enhances anti-tumor efficacy of PD1 pathway blockade by promoting intra tumor immune response via immunogenic tumor cell death and T cell intrinsic mechanisms. Cancer Research. 78(13_Supplement). 4549–4549. 8 indexed citations
8.
Tan, Bo, Sucai Dong, Robert L. Shepard, et al.. (2015). Inhibition of Nicotinamide Phosphoribosyltransferase (NAMPT), an Enzyme Essential for NAD+ Biosynthesis, Leads to Altered Carbohydrate Metabolism in Cancer Cells. Journal of Biological Chemistry. 290(25). 15812–15824. 38 indexed citations
9.
Phung, Thuy L., Wa Du, Qi Xue, et al.. (2014). Akt1 and Akt3 Exert Opposing Roles in the Regulation of Vascular Tumor Growth. Cancer Research. 75(1). 40–50. 40 indexed citations
10.
Tolcher, Anthony W., Jonathan H. Goldman, Amita Patnaik, et al.. (2014). A phase I trial of LY2584702 tosylate, a p70 S6 kinase inhibitor, in patients with advanced solid tumours. European Journal of Cancer. 50(5). 867–875. 45 indexed citations
11.
Brooks, Harold B., et al.. (2012). Basics of Enzymatic Assays for HTS. 180(7). 1687–700; discussion 1700. 24 indexed citations
12.
Tan, Bo, Debra A. Young, Tao Wang, et al.. (2012). Pharmacological Inhibition of Nicotinamide Phosphoribosyltransferase (NAMPT), an Enzyme Essential for NAD+ Biosynthesis, in Human Cancer Cells. Journal of Biological Chemistry. 288(5). 3500–3511. 135 indexed citations
13.
Geeganage, Sandaruwan, Lillian Sams, Leslie H. Brail, et al.. (2010). Abstract 352: Preclinical evaluation of LYS6K1, a novel, highly selective, orally bioavailable inhibitor of p70 S6 kinase currently in phase I clinical trials for cancer. Cancer Research. 70(8_Supplement). 352–352. 1 indexed citations
14.
15.
Davidson, Jennifer D., Liandong Ma, Michael Flagella, et al.. (2004). An Increase in the Expression of Ribonucleotide Reductase Large Subunit 1 Is Associated with Gemcitabine Resistance in Non-Small Cell Lung Cancer Cell Lines. Cancer Research. 64(11). 3761–3766. 249 indexed citations
16.
Geeganage, Sandaruwan & Perry A. Frey. (2002). Galactose-1-Phosphate Uridylyltransferase: Kinetics of Formation and Reaction of Uridylyl-Enzyme Intermediate in Wild-Type and Specifically Mutated Uridylyltransferases. Methods in enzymology on CD-ROM/Methods in enzymology. 354. 134–148. 2 indexed citations
17.
18.
Geeganage, Sandaruwan & Perry A. Frey. (1999). Significance of Metal Ions in Galactose-1-Phosphate Uridylyltransferase:  An Essential Structural Zinc and a Nonessential Structural Iron. Biochemistry. 38(40). 13398–13406. 20 indexed citations
19.
Ruzicka, Frank J., Sandaruwan Geeganage, & Perry A. Frey. (1998). Kinetic Mechanism of UDP-Hexose Synthase, a Point Variant of Hexose-1-Phosphate Uridylyltransferase from Escherichia coli. Biochemistry. 37(32). 11385–11392. 4 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Timothy G. Whitsett Breakdown of academic impact, for papers by Estefanía Carrasco‐García Breakdown of academic impact, for papers by Yidan Ren Breakdown of academic impact, for papers by Qinlian Jiao Breakdown of academic impact, for papers by Bojie Dai Breakdown of academic impact, for papers by David Cerna Breakdown of academic impact, for papers by Ji Nie Breakdown of academic impact, for papers by Wei Wei Prior Breakdown of academic impact, for papers by Demetra Constantinidou
Rankless by CCL
2026